Promega, JA3001, CTLA-4 Blockade Bioassay

Assay Performance Data
Accuracy and Precision are critical to bioassays and the development of biologics. The CTLA-4 Blockade Bioassay is both accurate and precise. Accuracy is a measure of how close results are to a target or reference value. Precision is a measure of repeatability. This assay was developed and prequalified according to ICH guidelines for accuracy and precision, giving it the performance characteristics required for many applications of a bioassay used for antibody drug discovery research and development.
Accuracy: Measure of ability to replicate a reference or "target" value.
IntraLab Precision: Measure of repeatability from multiple assays of the same homogeneous sample under the same operating conditions over a short time (same analyst; same lab; same day).
Intermediate Precision: Measure of repeatability of multiple assays of the same homogeneous sample with different analysts or equipment or on different days.
Linearity: Ability of the assay to provide measured values that are proportional to the concentration of the sample.
The CTLA-4 Blockade Bioassay Shows Precision, Accuracy and Linearity.
The CTLA-4 Blockade Bioassay reflects the mechanism of action (MOA) and specificity of biologics designed to block the CTLA-4/CD80 and CD86 interaction.
The CTLA-4 Blockade Bioassay measures the inhibitory activity of clinical grade anti-CTLA-4 blocking antibodies.
CTLA-4 Effector Cells were incubated with aAPC/Raji Cells in the absence or presence of anti-CTLA-4, anti-PD-1, anti-TIGIT or anti-HER2 blocking antibodies, as indicated.
CTLA-4 Effector Cells and aAPC/Raji Cells were incubated with increasing concentrations of anti-CTLA-4 antibody, ipilimumab, for 6 hours.